Oct 2024 $2 M No. 6 Under $2 million 8
Phylos Bioscience, Inc.: Raise no. 6, Oct 2024 × Investors in this round 8 investors had bought by the notice of Nov 1, 2024: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $4 M offered; $2 M still to sell
Smallest investment taken $100,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Oregon People named in the notice Barbara J Peachey · Executive Officer Nishan Karassik · Executive Officer, Director Ralph J Risch · Executive Officer, Director David J Patterson · Director Mina Mishrikey · Director Timothy J Gregory · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”Signed by Barbara Peachey, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 1, 2024. Read the notice at the SEC .
equity SEC Apr 2021 $3 M No. 5 $2 to $10 million 4
Phylos Bioscience, Inc.: Raise no. 5, Apr 2021 × Investors in this round 4 investors had bought by the notice of May 5, 2021: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $5 M offered; $3 M still to sell
Smallest investment taken $100,000
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Oregon People named in the notice Dylan J Anderson · Executive Officer Nishan Karassik · Executive Officer, Director Ralph J Risch · Executive Officer, Director David J Patterson · Director Timothy J Gregory · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”Signed by Dylan Anderson, Chief Financial Officer. Source: SEC Form D, newest notice filed May 5, 2021. Read the notice at the SEC .
equity, debt, options SEC Mar 2020 $5 M No. 4 $2 to $10 million 33
Phylos Bioscience, Inc.: Raise no. 4, Mar 2020 × Investors in this round 33 investors had bought by the notice of Jan 27, 2021: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $25 M offered; $20 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Oregon People named in the notice Nishan Karassik · Executive Officer, Director Ralph J Risch · Executive Officer, Director Scott J Bowman · Executive Officer David J Patterson · Director Timothy J Gregory · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”Signed by Scott Bowman, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 27, 2021. Read the notice at the SEC .
equity, debt SEC Jan 2020 $5 M No. 3 $2 to $10 million 25
Phylos Bioscience, Inc.: Raise no. 3, Jan 2020 × Investors in this round 25 investors had bought by the notice of Jan 23, 2025: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Oregon People named in the notice Barbara J Peachey · Executive Officer Nishan Karassik · Executive Officer, Director Ralph J Risch · Executive Officer, Director David J Patterson · Director Mina J Mishrikey · Director Timothy J Gregory · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount o which cannot be estimated at this time.”Signed by Barbara A. Peachey, Vice President, Finance. Source: SEC Form D and 2 amendments, newest notice filed Jan 23, 2025. Read the notice at the SEC .
equity SEC Apr 2019 $12 M No. 2 $10 to $50 million 33
Phylos Bioscience, Inc.: Raise no. 2, Apr 2019 × Investors in this round 33 investors had bought by the notice of Apr 19, 2021: 33 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $26 M offered; $14 M still to sell
Smallest investment taken $20,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Oregon People named in the notice Dylan J Anderson · Executive Officer Nishan Karassik · Executive Officer, Director Ralph J Risch · Executive Officer, Director David J Patterson · Director Timothy J Gregory · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”Signed by Dylan Anderson, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Apr 19, 2021. Read the notice at the SEC .
equity, options SEC Aug 2015 $1 M No. 1 Under $2 million 7
Phylos Bioscience, Inc.: Raise no. 1, Aug 2015 × Investors in this round 7 investors had bought by the notice of Sep 16, 2016: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $6 M offered; $4 M still to sell
Smallest investment taken $50,000
What was sold equity, debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Oregon People named in the notice Mowgli Holmes · Executive Officer, Director Nishan Karassik · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used to pay normal executive compensation, the amount of which cannot be estimated at this time.”Signed by Nishan Karassik, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 16, 2016. Read the notice at the SEC .
equity, debt, options SEC